About Myeloid-associated differentiation marker-like protein 2
Myeloid-associated differentiation marker-like protein 2 (MYADML2) is a protein
from Homo sapiens identified by UniProt accession
A6NDP7, 307 residues long.
MolForge cross-references it against 0 known binders and
22 disease associations.
Target properties
| Protein name | Myeloid-associated differentiation marker-like protein 2 |
|---|
| UniProt accession | A6NDP7 |
|---|
| Gene | MYADML2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 307 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (22)
Diseases linked to this target (Open Targets).
- vital capacity · score 0.19
- hair colour measurement · score 0.17
- birth weight · score 0.12
- peak expiratory flow · score 0.09
- HbA1c measurement · score 0.08
- refractive error measurement · score 0.08
- hepatocellular carcinoma · score 0.07
- hair color · score 0.07
- forced expiratory volume · score 0.06
- BMI-adjusted waist-hip ratio · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-A6NDP7-F1 | alphafold | PREDICTED | 86.38 | — |
Amino-acid sequence (307 residues)
MGSTMEPPGG AYLHLGAVTS PVGTARVLQL AFGCTTFSLV AHRGGFAGVQ GTFCMAAWGF CFAVSALVVA CEFTRLHGCL RLSWGNFTAA FAMLATLLCA TAAVLYPLYF ARRECSPEPA GCAARDFRLA ASVFAGLLFL AYAVEVALTR ARPGQVSSYM ATVSGLLKIV QAFVACIIFG ALVHDSRYGR YVATQWCVAV YSLCFLATVA VVALSVMGHT GGLGCPFDRL VVVYTFLAVL LYLSAAVIWP VFCFDPKYGE PKRPPNCARG SCPWDSQLVV AIFTYVNLLL YVVDLAYSQR IRFVPSL
Explore Myeloid-associated differentiation marker-like protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets